US 11,866,490 · Application 17/469,044 · Granted Jan 9, 2024
US 11,866,490
Antibody that binds to vegf and il-1beta and methods of use
Estimated expiration
March 23, 2040
13y 202d remaining
Earliest effective filing
Dec 20, 2019
+ 20 years
Dec 20, 2039
PTA +94d
Mar 23, 2040
No TD
—
Final
Mar 23, 2040
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- September 8, 2021
- Earliest effective filing
- December 20, 2019
- Issue date
- January 9, 2024
- PTA
- +94 days
- Base expiry (before PTA)
- December 20, 2039
December 20, 2019 + 20 years = December 20, 2039 + 94 PTA days = March 23, 2040
- Divisional of application 16/722,317, filed Dec 20, 2019, issued as US 11,130,804
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 17/469,044 · US 11,866,490
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 11,866,490: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11866490Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.